This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital malformation syndromes involving early overgrowth조기과성장을 포함하는 선천기형증후군

ItemDetails
A. Classification codesICD-10: Q87.3 | Special Copayment Reduction: V244 | Re-certification cycle: 5 years
B. SynonymsSotos syndrome, Weaver syndrome
C. Adult onsetMainly diagnosed in childhood, but mild phenotypes are sometimes first found in adulthood; intellectual disability and behavioral problems persist into adulthood
SectionSummary
1. HistorySotos syndrome described by Sotos in 1964; NSD1 gene identified in 2002. Weaver syndrome described in 1974; EZH2/NSD1 variants identified. Both have been redefined as epigenetic disorders related to histone methylation.
2. CausesSotos: NSD1 (5q35) variants (deletions or point mutations). Weaver: EZH2 (7q36.1) or NSD1 variants. Both genes are histone H3 methyltransferases that regulate growth through chromatin remodeling.
3. GeneticsAutosomal dominant inheritance; about 95% of Sotos cases are de novo NSD1 variants. 5q35 microdeletions are common in Japan, whereas point variants predominate in Western populations. EZH2-variant Weaver has a high de novo rate.
4. General epidemiologySotos syndrome: about 1/14,000~1/20,000 births. Weaver syndrome: about 1/100,000 births or fewer (rare). Occurs in all ethnic groups worldwide. No sex difference.
5. PathophysiologyNSD1/EZH2 deficiency → reduced histone H3K36me2 (NSD1) or H3K27me3 (EZH2) → dysregulated expression of growth-related genes (IGF2, IGFBP2, etc.) → early overgrowth and neurodevelopmental abnormalities.
6. SymptomsMacrocephaly, tall stature, distinctive face (Sotos: broad forehead and pointed chin; Weaver: round, broad forehead), developmental delay and intellectual disability, motor developmental delay. Limited joints and a hoarse voice are also characteristic of Weaver.
7. SignsFrom birth, overgrowth of height, weight, and head circumference all +2SD or more, advanced bone age, large and broad hands and feet, distinctive skin (thin skin, prominent veins), persistent tall stature.
8. ScreeningThe combination of neonatal overgrowth (head circumference, height, weight +2SD or more) + distinctive facial findings is the screening clue. Refer children deviating from growth curves for molecular genetic testing.
9. DiagnosisAfter clinical diagnostic criteria (overgrowth + macrocephaly + distinctive face), NSD1 gene analysis (point variants + deletion MLPA); if negative, an overgrowth panel including EZH2 or WES. Bone age X-ray is essential.
10. TreatmentNo curative treatment; early developmental intervention (speech, cognitive, behavioral therapy), learning support, drug and behavioral treatment of behavioral problems (ADHD, autism), monitoring for malignant tumors, obesity management.
11. PrognosisOvergrowth normalizes after puberty. Intellectual disability is mild to moderate, and most can live semi-independently. Somewhat increased risk of malignant tumors (especially in childhood). Overall a relatively good prognosis.
12. PreventionGenetic counseling, prenatal genetic diagnosis (high de novo rate, so recurrence risk is low), preimplantation genetic testing (PGT-M) when there is a family history, linkage to early developmental support programs.
13. References10 recent references (with PMID/DOI)

1. History

The main representative diseases of Congenital malformation syndromes involving early overgrowth, classified under code Q87.3, are Sotos syndrome and Weaver syndrome. Both diseases share as common features overgrowth prominent from birth, a distinctive facial appearance, and developmental delay, and at the molecular level they share a common etiology of histone methyltransferase dysfunction.

Sotos syndrome was named when the American pediatric endocrinologist Juan F. Sotos first described, in 1964, five children with overgrowth, macrocephaly, a distinctive face (frontal bossing, pointed chin), and developmental delay. It was initially also called cerebral gigantism, but once it became clear that it was unrelated to excess growth hormone secretion, the name Sotos syndrome became established. In the 1970s~90s, an autosomal dominant mode of inheritance was established through clinical descriptions and family history analysis. The decisive molecular identification came in 2002 when Kurotaki et al. first reported deletions of the NSD1 (nuclear receptor SET-domain-containing protein 1) gene at 5q35 on the long arm of chromosome 5 in Japanese patients with Sotos syndrome. Subsequently, many NSD1 point mutations were also reported in Western patients, establishing NSD1 as the main causative gene of Sotos syndrome.

Weaver syndrome was named when the American physician James Weaver first described, in 1974, two children with overgrowth, a distinctive face (round, broad forehead, small chin), joint contractures, and a hoarse voice. It is clinically similar to Sotos syndrome but differs in facial appearance and specific symptoms. The molecular basis was identified in 2011 when Gibson et al. showed that variants in the EZH2 (enhancer of zeste homolog 2) gene cause Weaver syndrome. EZH2 is a core component of polycomb repressive complex 2 (PRC2), which catalyzes histone H3K27 trimethylation. Subsequently, NSD1 variants were also reported to be able to cause the Weaver syndrome phenotype, confirming molecular overlap between the two syndromes. In the 2010s, a conceptual shift took place in which these were reclassified as an epigenetic mechanistic group of overgrowth syndromes.

2. Causes

The overgrowth syndromes in this category are caused by abnormalities of genes encoding histone methyltransferases.

The cause of Sotos syndrome is pathogenic variants of the NSD1 gene located at 5q35 on the long arm of chromosome 5. The NSD1 protein is a histone methyltransferase (containing a SET domain) that methylates lysine 36 of histone H3 (H3K36me2), and it is an epigenome regulator that keeps chromatin structure open or regulates the expression of specific genes. NSD1 haploinsufficiency is the basic etiology of Sotos syndrome. In terms of variant type, 5q35 microdeletions (including the entire NSD1 gene and surrounding regions) account for about 50~60% in Japanese patients, whereas point mutations (missense, nonsense, splicing, small insertions/deletions) are more common in Western patients (about 60~70%). This difference is understood to be associated with founder effects or regional differences in genomic structure.

The main cause of Weaver syndrome is pathogenic variants of the EZH2 (7q36.1) gene. EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), an enzyme that trimethylates lysine 27 of histone H3 (H3K27me3). Because H3K27me3 is a repressive mark that suppresses the expression of developmental genes, EZH2 deficiency causes overgrowth through abnormal activation of developmental programs. Besides EZH2 variants, NSD1, EED, and SUZ12 variants have been reported to cause Weaver syndrome or a Weaver-like phenotype, and these all encode components of the PRC2 complex.

Therefore, Sotos and Weaver syndromes are both understood collectively as epigenetic overgrowth syndromes caused by abnormal histone methylation, and dysregulation of growth factor pathways (IGF1, IGF2, IGFBP), the WNT pathway, and the MAPK/ERK pathway is proposed as the common mechanism of overgrowth and neurodevelopmental abnormalities.

3. Genetics

Sotos syndrome is inherited in an autosomal dominant manner, and about 95% or more of patients arise from de novo NSD1 variants. Inheritance from a parent occurs in around 5%, and in these cases one of the parents also shows a mild or full Sotos syndrome phenotype. Expressivity is highly variable, so even within a family with the same NSD1 variant, clinical phenotypes ranging from mild to moderate can appear. Penetrance is near-complete.

The NSD1 gene is located at 5q35.3 on chromosome 5 and consists of 23 exons. Among point mutations, missense variants are the most common, and variants that impair SET domain function tend to be associated with severe phenotypes. 5q35 microdeletions may include not only NSD1 but also adjacent genes (FGFR4, MAPK9, etc.), so patients with microdeletions may show additional clinical features (such as an increased frequency of congenital heart defects).

Weaver syndrome is also autosomal dominant and is mostly caused by de novo EZH2 variants. EZH2 is located at 7q36.1 and consists of 20 exons. EZH2 variants tend to cluster in the SET domain region, and variants in this region impair the catalytic function of H3K27 methylation. Activating EZH2 variants (gain-of-function), conversely, cause pediatric B-cell lymphoma (EZH2-mutant lymphoma), so they must be distinguished from the loss-of-function variants of Sotos/Weaver syndrome.

Because the de novo variant rate is high, even when both parents are normal, the recurrence risk in their children is similar to that of the general population, apart from the possibility of germline mosaicism (about 1~3%). However, when the patient reaches reproductive age, there is a 50% risk of transmission to their children.

4. General epidemiology

The birth prevalence of Sotos syndrome is reported at about 1/14,000~1/20,000 births. Some studies report up to 1/10,000, a relatively high frequency among rare diseases. It occurs in all ethnic groups and regions worldwide, and there is no sex difference. In Japan, 5q35 microdeletions account for a relatively high proportion, and as a result Japanese genomic data on Sotos syndrome are abundant. In Western countries, point mutations are the main cause. With clarification of diagnostic criteria and improved access to molecular genetic testing, the diagnosis rate has recently been rising.

The prevalence of Weaver syndrome is much lower, estimated at 1/100,000 births or fewer, and several hundred patients have been reported worldwide. Because it is rarer than Sotos syndrome, clinical experience is relatively limited, but with the spread of EZH2 gene testing the number of diagnosed patients is gradually increasing. It occurs without sex difference and has been reported in all ethnic groups.

Both syndromes fall under Special Copayment Reduction V244, and in Korea as well, case finding through active molecular diagnosis is needed in children presenting with overgrowth and developmental delay. In particular, in children with overgrowth, after excluding excess growth hormone secretion and other endocrine causes, it is recommended to perform overgrowth syndrome panel testing that includes Sotos syndrome.

5. Pathophysiology

The core pathophysiology of Sotos and Weaver syndromes is failure of epigenetic growth regulation due to abnormal histone methylation.

NSD1 (Sotos) mechanism: H3K36me2, catalyzed by NSD1, keeps chromatin in an open state (euchromatin), promoting transcriptional activation of related genes, while at the same time competitively blocking repression by H3K27me3, thereby maintaining the overall balance of chromatin states. A proposed mechanism with NSD1 deficiency is reduced H3K36me2 → expansion of H3K27me3 → over-repression of growth-suppressing genes → early overgrowth. NSD1 also interacts with growth-suppressing transcription factors (e.g., regulation of EZH2 substrates) to regulate cell proliferation.

In NSD1 deficiency, abnormal expression of insulin-like growth factor 2 (IGF2) and IGF-binding proteins (IGFBP) has been reported, and abnormal activation of the growth hormone-IGF axis may contribute to overgrowth. Overall derailment of growth regulatory programs during embryonic development causes overgrowth from before birth.

EZH2 (Weaver) mechanism: H3K27me3, catalyzed by EZH2, is central to transcriptional repression of developmental genes (HOX genes, etc.). With EZH2 deficiency (loss-of-function), reduced H3K27me3 → abnormal expression of developmental regulatory genes → early overgrowth, abnormal cartilage and bone development, and neurodevelopmental abnormalities appear. A mechanism has also been proposed in which loss of EZH2 function releases repression of cell cycle regulators (CDKN2A, CDKN2B, etc.), leading to increased cell proliferation.

As for the mechanism of neurodevelopmental abnormalities, NSD1/EZH2 deficiency is understood to cause abnormalities in neural stem cell differentiation programs, affecting synapse formation and the establishment of neural circuits. Evidence is accumulating that the expression of several synaptic protein genes involved in autism spectrum disorder and intellectual disability is regulated by these two histone methyltransferases.

The mechanism of the increased risk of malignant tumors is related to the fact that NSD1 and EZH2 have tumor-suppressor functions. NSD1 deficiency is also observed in acute myeloid leukemia (AML) and certain solid cancers, and EZH2 deficiency acts as a risk factor for some hematologic malignancies.

6. Symptoms

Sotos syndrome

From birth, marked overgrowth appears, with height, weight, and head circumference all 2 standard deviations or more above the norm. This overgrowth continues throughout childhood, and after puberty the growth rate normalizes, so adult height is often in the upper normal range. Macrocephaly is particularly prominent and sometimes reaches +4SD or more above the norm in childhood.

Distinctive facial findings include a broad, forward-protruding forehead (prominent forehead), a long, narrow head shape (dolichocephaly), widely spaced eyes (hypertelorism), down-slanting palpebral fissures, a high-arched palate or cleft palate, and a pointed, small chin (pointed chin). This facial pattern changes with age and is less prominent in adulthood. The hands and feet are large and broad, the pelvis is wide, and hypotonia is common in the neonatal period.

Developmental delay is global, with language delay especially prominent. Intellectual disability is mild to moderate (IQ about 40~80), and a few show borderline intelligence. The behavioral phenotype commonly includes ADHD, autism spectrum disorder (about 18%), impulsivity, and sensory hypersensitivity. Seizures (epilepsy) occur in about 25%. Heart defects (VSD, ASD, PDA, etc.) are reported in about 20%. Urinary tract abnormalities (structural kidney abnormalities, vesicoureteral reflux) may be present.

Weaver syndrome

It shows overgrowth and developmental delay similar to Sotos syndrome but differs in facial appearance. Weaver syndrome is characterized by a round, broad forehead, large ears, midface hypoplasia, a short philtrum, micrognathia, down-slanting palpebral fissures, and wide hypertelorism. Joint contractures (fingers, elbows, knees) are more prominent than in Sotos. A hoarse voice (hoarse cry, hoarse voice) is characteristically present from the neonatal period. Urinary tract abnormalities and inguinal/umbilical hernias may be present. Advanced bone age also appears, similar to Sotos.

7. Signs

Growth parameters: Birth length >52cm and head circumference >37cm are common, and height, weight, and head circumference all lie at or above the 97th percentile on standard growth curves. The growth rate is rapid throughout childhood and normalizes around puberty. Adult height is about 180~195cm in men and about 170~185cm in women, often exceeding the upper normal limit.

Skeletal findings: A characteristic finding on wrist/hand radiographs is bone age advanced by 2~4 years or more beyond chronological age. The fingers are long, the palms broad, and both feet excessively large. Long bone length measurements also confirm excessive overgrowth of long bone length for age.

Neurological findings: Hypotonia in the neonatal period to infancy is characteristic, causing feeding difficulties and motor developmental delay (walking at an average of 15~22 months). On MRI, abnormal corpus callosum formation, ventricular enlargement, and abnormal cerebellar development are observed in some.

Ophthalmologic findings: Refractive errors (myopia, hyperopia), strabismus, and optic disc abnormalities are reported. Fundus and refraction examinations are needed from early on.

Other findings: Thin skin with prominent veins is a characteristic skin finding. Polyhydramnios during pregnancy may be observed on prenatal ultrasound. Jaundice is common in the neonatal period. In Weaver syndrome, the hoarse voice sometimes persists into adulthood.

8. Screening

Screening for these syndromes begins with clinical recognition. Overgrowth is not a common reason for pediatric visits, but when overgrowth is accompanied by developmental delay or distinctive facial findings, a hereditary overgrowth syndrome must be suspected.

Neonatal screening: In neonates with birth length, weight, and head circumference +2SD or more above the norm, Sotos or Weaver syndrome is suspected when distinctive facial findings (broad forehead, pointed chin, down-slanting palpebral fissures) are present. When macrocephaly and overgrowth are observed on prenatal ultrasound, referral for genetic testing right after birth is possible. Neonatal hypotonia and feeding difficulties are also early clues for suspicion.

Screening in infancy and childhood: In children in whom regular growth monitoring confirms a persistent tendency toward overgrowth accompanied by developmental delay, endocrine causes such as excess growth hormone secretion (pituitary tumor) and thyroid dysfunction are excluded first, and then a hereditary overgrowth syndrome panel test is performed. Confirmation of advanced bone age on bone age X-ray (wrist radiograph) supports the diagnosis.

Family history-based screening: When one parent has a confirmed diagnosis (a rare situation), the parents are informed of the 50% recurrence risk in their children, and genetic testing right after birth or prenatally is recommended. Because most variants are de novo, the recurrence risk in families of confirmed patients is low, but the possibility of germline mosaicism (1~3%) is disclosed during genetic counseling.

9. Diagnosis

Clinical diagnostic criteria

The clinical diagnosis of Sotos syndrome is based on the combination of three core elements: (1) distinctive face (frontal bossing, down-slanting palpebral fissures, pointed chin), (2) overgrowth (height or head circumference +2SD or more), (3) developmental delay and intellectual disability. A clinical diagnosis is possible when all three are met. Advanced bone age is also a supporting finding.

The clinical diagnosis of Weaver syndrome is based on the combination of overgrowth, distinctive face (round, broad forehead, micrognathia), joint contractures, and a hoarse voice. Facial appearance and the presence of joint contractures help in the clinical differentiation from Sotos.

Molecular genetic diagnosis

In Sotos syndrome, direct sequencing of the NSD1 gene (NGS or Sanger) and NSD1 deletion MLPA are first performed simultaneously. If NSD1 variants are negative, an overgrowth syndrome panel (including EZH2, NSD1, EED, SUZ12, HIST1H1E) or whole exome sequencing (WES) is performed. In Weaver syndrome, EZH2 sequencing is performed first, and if negative, testing is expanded to a gene panel related to the PRC2 complex.

Supplementary tests

Bone age X-ray (wrist), brain MRI (evaluation of the corpus callosum, ventricles, cerebellum), echocardiography (presence of structural defects), abdominal/renal ultrasound (urinary tract malformations, tumor screening), ophthalmologic examination (refractive errors, optic nerve abnormalities), hearing tests, and developmental assessment (psychological tests, developmental scales) are included at initial diagnosis.

10. Treatment

There is currently no curative treatment (gene therapy, enzyme replacement, etc.) for Sotos and Weaver syndromes, and treatment consists of multidisciplinary symptomatic support for each symptom and complication.

Developmental support

Early developmental intervention is the most important factor for improving prognosis. Speech therapy (language delay), occupational therapy (fine motor skills, sensory integration), and physical therapy (hypotonia, gait development) are started early after birth. At school age, learning assistance is needed through special education support or in an inclusive education setting. Because language development is slow, introduction of augmentative and alternative communication (AAC) devices is considered early.

Behavioral and mental health treatment

For ADHD, behavioral therapy and drug therapy such as methylphenidate are combined. When autism spectrum disorder is present, structured interventions including ABA (applied behavior analysis) therapy are needed. Drug and non-drug treatments for anxiety, impulsivity, and sensory hypersensitivity are individualized.

Management of complications

When seizures are present, antiepileptic drug (AED) treatment is given. Heart defects are treated with standard treatment according to type (percutaneous closure, surgery). When there are kidney abnormalities, urinary tract infection prevention and renal function monitoring are carried out in collaboration with urology. Because there is a tendency toward obesity, dietary guidance and regular exercise are recommended.

Tumor surveillance

There are reports that the risk of malignant tumors (leukemia, neuroblastoma, Wilms tumor, etc.) in Sotos syndrome is slightly higher than in the general population. Periodic abdominal ultrasound (renal tumor screening) and blood tests (monitoring for blood count abnormalities) are recommended. Because a risk of malignant tumors has also been reported in Weaver syndrome, similar surveillance is needed.

11. Prognosis

The overall prognosis of Sotos and Weaver syndromes is relatively good, but intellectual disability and behavioral problems have a continuing impact on quality of life.

Growth prognosis: Overgrowth normalizes as the growth plates close at puberty and the growth rate normalizes. Adult height is in the upper normal range or slightly above, and in terms of physical function, tall stature itself is not a major problem.

Cognitive and behavioral prognosis: Intellectual disability is mild to moderate, and early educational intervention is clearly effective. Many patients can lead semi-independent lives in adulthood (supported housing, assisted employment). Language ability is delayed but gradually improves into adulthood. Some (about 5~15%) show borderline or normal intelligence, and these patients can live independently.

Prognosis of complications: Epilepsy can mostly be controlled with antiepileptic drugs. Heart defects have a good cardiac prognosis with appropriate treatment. Malignant tumors are rare but greatly influence prognosis when they occur, so early detection is important.

Life expectancy: Without severe complications, a normal or near-normal life expectancy can be expected. Childhood malignant tumors and cardiac complications are the main causes of early death.

12. Prevention

Because Sotos and Weaver syndromes mostly occur sporadically due to de novo variants, preconception prevention is limited. However, the following preventive approaches are possible.

Genetic counseling: Parents of a child with Sotos or Weaver syndrome are counseled about the nature of de novo variants and the recurrence risk (germline mosaicism 1~3%). When one parent has the syndrome (rare, but it occurs), they are informed that there is a 50% risk of transmission to their children, and prenatal genetic diagnosis is recommended.

Prenatal genetic diagnosis: In families in which the causative variant has been identified, fetal NSD1/EZH2 gene analysis is possible by CVS at 10~12 weeks of gestation or amniocentesis at 15~18 weeks of gestation. In families with de novo variants, the recurrence risk is low, so prenatal diagnosis is not mandatorily recommended for every pregnancy, but it can be performed if desired.

Preimplantation genetic testing (PGT-M): Because it is an autosomal dominant disease, when a patient plans a pregnancy, transmission to children can be prevented by IVF and PGT-M, selecting and transferring embryos that do not carry the variant.

Secondary prevention (early diagnosis and intervention): Early diagnosis and early developmental intervention in children with overgrowth are the core of secondary prevention. Improved awareness of overgrowth syndromes among pediatricians and developmental pediatricians raises the early diagnosis rate, allowing developmental support and complication surveillance to start early. It is recommended to include neonatal overgrowth screening (standard deviation measurement of head circumference and length) in routine newborn examinations.

13. References

  1. Sotos JF, Dodge PR, Muirhead D, Crawford JD, Talbot NB. Cerebral gigantism in childhood: a syndrome of excessively rapid growth and acromegalic features and a non-progressive neurologic disorder. N Engl J Med. 1964;271:109-116. PMID: 14149512
  2. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet. 2002;30(4):365-366. PMID: 11896750
  3. Gibson WT, Hood RL, Zhan SH, et al. Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet. 2012;90(1):110-118. PMID: 22177091
  4. Tatton-Brown K, Rahman N. Sotos syndrome. Eur J Hum Genet. 2007;15(3):264-271. PMID: 17213838
  5. Leventopoulos G, Kitsiou-Tzeli S, Kritikos K, et al. A clinical study of Sotos syndrome patients with review of the literature. Pediatr Neurol. 2009;40(5):357-364. PMID: 19380071
  6. Weaver DD, Graham CB, Thomas IT, Smith DW. A new overgrowth syndrome with accelerated skeletal maturation, unusual facies, and camptodactyly. J Pediatr. 1974;84(4):547-552. PMID: 4822111
  7. Luscan A, Laurendeau I, Malan V, et al. Mutations in SETD2 cause a novel overgrowth condition. J Med Genet. 2014;51(8):512-517. PMID: 24951543
  8. Tatton-Brown K, Murray A, Hanks S, et al. Weaver syndrome and EZH2 mutations: clarifying the clinical phenotype. Am J Med Genet A. 2013;161A(12):2972-2980. PMID: 24115414
  9. Baujat G, Rio M, Rossignol S, et al. Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome. Am J Hum Genet. 2004;74(4):715-720. PMID: 15024691
  10. Tatton-Brown K, Hanks S, Ruark E, et al. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget. 2011;2(12):1127-1133. PMID: 22190405